Print
Email

Email

Mirum Pharmaceuticals Says FDA Approves Tablet Formulation of Treatment for Cholestatic Pruritus

Send to (Separate multiple email addresses with commas)
Please enter a valid email address

Your email address
Please enter a valid email address

Message (Optional)

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

Email

Your email has been sent.
Share
Share
Mirum Pharmaceuticals Says FDA Approves Tablet Formulation of Treatment for Cholestatic Pruritus

Clicking a link will open a new window.
Default text size A
Larger text size A
Largest text size A

Mirum Pharmaceuticals Says FDA Approves Tablet Formulation of Treatment for Cholestatic Pruritus

, MT Newswires - 10:26 AM ET 4/14/2025 Company News

10:26 AM EDT, 04/14/2025 (MT Newswires) -- Mirum Pharmaceuticals ( MIRM ) said Monday the US Food and Drug Administration has approved a new tablet formulation of Livmarli to treat cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestatis.

Livmarli tablets are expected to be available through Mirum Access Plus in June, the company said.

Price: 39.56, Change: -0.02, Percent Change: -0.06

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.

© 1999-2025 Midnight Trader, Inc. All rights reserved.

Mirum Pharmaceuticals Says FDA Approves Tablet Formulation of Treatment for Cholestatic Pruritus

Important legal information about the e-mail you will be sending. By using this service, you agree to input your real e-mail address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an e-mail. All information you provide will be used by Fidelity solely for the purpose of sending the e-mail on your behalf.The subject line of the e-mail you send will be "Fidelity.com: "

Your e-mail has been sent.

Your e-mail has been sent.

Ozempic copies restricted after US judge denies injunction

Reuters - 38 minutes ago
US plans Alaska LNG summit, will urge Japan, South Korea to support project

Reuters - 43 minutes ago
Alleged 'Scattered Spider' member extradited to US from Spain, Bloomberg reports

Reuters - 9:16 PM ET 4/24/2025
Trade tensions are giving Intel's older chips a second life

Reuters - 8:49 PM ET 4/24/2025
Trade tensions are giving Intel's older chips a second life

Reuters - 8:44 PM ET 4/24/2025
IMF focused on stability but will support countries on climate risks, Georgieva says

Reuters - 8:41 PM ET 4/24/2025
Harvard University exploring $1 billion of private equity stakes sale, source says

Reuters - 8:27 PM ET 4/24/2025

Content for this page, unless otherwise indicated with a Fidelity pyramid logo, is selected and published by Fidelity Interactive Content Services LLC ("FICS"), a Fidelity company. All Web pages published by FICS will contain this legend. FICS was established to present users with objective news, information, data and guidance on personal finance topics drawn from a diverse collection of sources including affiliated and non-affiliated financial services publications. Content selected and published by FICS drawn from affiliated Fidelity companies is labeled as such. FICS-selected content provided is not intended to provide tax, legal, insurance, or investment advice, and should not be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by any Fidelity entity or any third party. Quotes are delayed unless otherwise noted. FICS is owned by FMR LLC and is an affiliate of Fidelity Brokerage Services LLC. Terms of use for Third-Party Content and Research

These links are provided by Fidelity Brokerage Services LLC ("FBS") for educational and informational purposes only. FBS is responsible for the information contained in the links. FICS and FBS are separate but affiliated companies and FICS is not involved in the preparation or selection of these links, nor does it explicitly or implicitly endorse or approve information contained in the links.

Before investing, consider the funds' investment objectives, risks, charges, and expenses. Contact Fidelity for a prospectus or, if available, a summary prospectus containing this information. Read it carefully.